INTRODUCTION
Bisphosphonates are widely used in the management of metastatic disease to the bone, Paget's disease and in the treat ment of osteoporosis. 1 They are capable of localising to bone and have a strong affinity with osteoclasts, inhibiting their function. 2 Bisphosphonates bind to exposed bone mineral around resorbing osteoclasts and thus disturb osteoclast mediated bone resorption, and decrease bone turnover. At a cellular level, the drugs inhibit the recruitment of osteo clasts and initiate apoptosis at the bone surface, including reducing the life-span. This may possibly be due to stimulation of osteoclast inhibitory factor, prevention of osteoclast development from bone mar row precursors, and down regulation of matrix metalloproteinases. [2] [3] [4] [5] [6] It is thought that bisphosphonates modulate osteoclast function by interacting with cell surface receptor or an intracellular enzyme.
Despite uncertainty regarding the exact method of action of bisphospho nates, their role in decreasing osteoclast mediated lysis of bone has been well established in clinical trials. They have been shown to reduce skeletal tumour load in patients with multiple myeloma, breast cancer and prostate cancer. 5 It has recently been reported that bisphospho nates are capable of causing osteoche monecrosis of the jaws. 1, 3, [5] [6] [7] It is seen predominantly in intravenously-admin istered bisphosphonates, mainly pamidr onate (Aredia) and zoledronate (Zometa), indicated for the management of hyper calcaemia of malignancy. However, it has also been reported in patients tak ing oral bisphosphonates, alendronate (Fosamax) and risedronate (Actonel), used in the management of osteoporo sis and Paget's disease. Pamidronate and zoledronate are nitrogen-containing bisphosphonates, are much more potent and are not metabolised. Therefore they accumulate in bone and have an ongo ing effect that results in bone necro sis. 1, [3] [4] Ibandronate is a single-nitrogen bisphosphonate, available in IV or oral formulations, with similar effi cacy for treatment of metastatic bone disease.
The other main risk factors for osteonecrosis of the jaw are invasive dental procedures and poor oral hygiene, corticosteroid therapy and radiation therapy. 9 We describe a case of osteochemon ecrosis of the maxilla associated with long-term bisphosphonate therapy for metastatic breast cancer.
CASE REPORT
A 51-year-old female was referred ini tially by the Specialist Registrar in clin ical oncology regarding problems with her dentition, mainly brittle teeth and halitosis. She was subsequently referred to the Multi-Disciplinary Head and Neck team regarding a suspicious lesion in the upper right maxilla (Fig. 1) .
Her past medical history included breast cancer for which she underwent a wide local excision and axilliary clear ance in October 2000. A six cycle chem otherapy regime was given over three months which included: cyclophospha mide, methotrexate and 5-fl uoroucil. Isotope bone scan confi rmed skeletal metastasis in the left shoulder where an isolated fraction of radiotherapy was given. She commenced oral Clodronate At the time of presentation, the patient reported pain and swelling in the cheek, problems with blowing her nose on the right hand side, weight loss and also bad breath.
On examination, there was: marked halitosis, extensive dental caries in her lower dentition, and a large bony defect in the upper right quadrant of the max illa mainly involving the buccal alveo lus. This lesion seemed highly suspicious of carcinoma, either a primary of the oral mucosa or a secondary metastasis from her primary breast cancer.
Initial radiographic examination with an occipitomental facial view (Fig. 2) showed non-specific features (radio pacity of the right maxillary antrum) and did not highlight the magnitude of the lesion.
An urgent biopsy under local anaes thesia was carried out with two speci mens taken: one of a segment of bone from the right maxilla and the other palatal mucosa adjacent to the necrotic bone.
The pathology report indicated frag ments of bone showing osteonecrosis with no evidence of metastasis. The palatal mucosa showed only infl amma tion with no evidence of ulceration or neoplasia. On review, the patient had a marked fenestrated/sequestrated area in the right maxilla which has all the fea tures of neoplasia.
As a result, the patient underwent further exploration and biopsy of both bone and soft tissue of the right maxilla under general anaesthesia. Examination and exploration revealed an extensive area of necrotic bone and soft tissue in the maxilla.
The histopathology report showed moderate to severe, acute and chronic inflammation with extensive mucosal ulceration. This included colonies of actinomycete organisms. Again there was no evidence of dysplasia or malig nancy in the biopsy sections. A diag nosis of osteonecrosis of the maxilla associated with the use of bisphospho nates was therefore made.
Initial treatment and management included removal of sequestrated areas of necrotic bone on three occasions. Long term antibiotic therapy was commenced to deal with any superadded infection -150 mg clindamycin being the drug of choice. Her analgesic requirements were addressed requiring the use of opioid and non-opioid medication. She is at present stable with no further bony destruction apparent.
In addition to the regime instigated for her presenting condition a full oral assessment was carried out to address the needs of her oral hygiene and condition of her remaining dentition. A treatment plan was prescribed in consultation with our restorative colleagues to facilitate rehabilitation of soft and hard tissues.
As indicated she had suffered a degree of weight loss because of her reduced dietary intake due to both pain and functional impairment. Her nutritional status was assessed and appropriate sup plementation provided after input from our dietician within the multi-discipli nary team environment.
A reconstructive option is planned with a prosthesis to obturate the defect in the fi rst instance.
DISCUSSION
Bisphosphonate-mediated inhibition of osteoclast function seems to decrease bone resorption and inhibit normal bone turnover remodelling. Bone resorp tion and remodelling play an essen tial role in maintaining normal bone homeostasis. As osteoclasis occurs, cytokines and growth factors are released into surrounding matrix essential for modulating new bone development. 1, 5 However, bisphosphonates may alter bone homeostasis suffi ciently that the ability of bone to heal after minor insults is compromised. The bone may also become secondarily infected and seques trate, leading to a lesion that appears clin ically similar to osteoradionecrosis. 3, 10 Pathogenesis of the osteonecrotic proc ess is most consistent with localised vas cular insufficiency. This is believed to be important in reducing tumour burden by depriving tumour cells of adequate nutrients and blood supply. However, if osteoclastic function is too severely impaired, osteocytes are not replaced and the capillary network in the bone is not maintained, resulting in avascular bone necrosis. 3, 5, 10 A retrospective review of 63 patients who presented with refractory osteomy elitis and history of chronic bisphospho nate therapy was performed. Fifty-six patients had received IV bisphospho nates for various malignant diseases (seven for osteoporosis). The presenting lesions were either non-healing extrac tion socket or an exposed jawbone-both being refractory to conservative debri dement and antibiotic therapy. 1 This is supported by a study of 36 patients with painful bone exposures in the jaws that were unresponsive to surgical or medical treatments. 4 Another report describes 17 patients with cancer with bone metas tases who subsequently developed osteonecrosis of the jaws. 7 Spontaneous exposure of bone may be due to thinness of the oral mucosa, with the mandibular lingual plate, tori, the mylohyoid ridge and the internal oblique ridge frequently involved in osteonecrosis.
Ibandronate-associated osteochem onecrosis of the jaw seems to be a rare adverse effect due to the small number of cases (seven). It was observed only in patients being treated for metastatic bone disease, but the association was confounded by prior treatment with an alternative bisphosphonate. 10 In this particular case the patient had over a five-year period received a combi nation of both IV bisphosphonate therapy and oral therapy which may well have made her at high risk of developing the condition. Concomitant medication dur ing these five years includes chemother apy agents as mentioned previously as well as hormone antagonists Tamoxifen, Exemestane and Anastrozole. This poses the question of synergistic activity with bisphosphonates.
At present, there is no effective treat ment for the condition. Surgical inter vention tends to expose further bone and locating viable bone margins is problematic. Covering exposed bone with tissue flaps is ineffective because of development of fi stulae around the fl aps. 1, 5 Because osteonecrosis and its complications can result in signifi cant chronic pain, dysfunction and disfi g urement which are difficult to treat, the aim should be prevention. 2 Dental surgery seems to be a precipitat ing event in development of most cases of bisphosphonates-related osteochem onecrosis. 4 It is therefore imperative that patients receiving necessary treatment have their dental status assessed prior to bisphosphonate therapy. This includes control of dental caries and periodontal disease, avoiding dental implant place ment, using soft liners on dentures, and to recommend an alternative to tooth extrac tions for patients with history of receiving bisphosphonate therapy. [4] [5] [6] [7] This is because withdrawal of bisphosphonate therapy before major dental procedures does not appear to hasten recovery of osteonecrosis due to their persistence in bone. 3 In established cases, the primary goals are palliation and control of osteomy elitis. Progression of disease usually controlled with antibiotics and periodic surgical debridement of sequestrating bone and wound irrigation. 5 However, these have proven consistently ineffec tive. 2 Surgical treatment should only be reserved for symptomatic patients.
It is important to make health care professionals and patients aware of the potential risk. There should be greater collaboration between medical oncolo gists, oral and maxillofacial surgeons and dentists.
